Abstract
The interaction of human platelet thrombospondin (TSP) with human platelet glycoproteins GPIIb-IIIa was studied using a solid-phase binding assay. Polystyrene test tubes were coated with TSP, and 125I-labeled GPIIb-IIIa was added, allowed to bind, and the bound radioactivity was measured. After 90 min, the binding became time independent, and in most experiments, more than 10% of the exogenously added radioactivity was bound to the tube. Analysis of the bound radioactivity by polyacrylamide gel electrophoresis and autoradiography indicated that it was from labeled GPIIb-IIIa. Several lines of evidence indicate that the binding of GPIIb-IIIa to TSP was specific. (a) TSP immobilized on plastic or Sepharose bound 3-10-fold more GPIIb-IIIa than immobilized bovine serum albumin. (b) Addition of unlabeled excess GPIIb-IIIa reversed the binding of 125I-labeled GPIIb-IIIa to immobilized TSP. (c) Addition of EDTA inhibited the binding of GPIIb-IIIa to TSP by more than 90%, whereas addition of 1 mM CaCl2 and 1 mM MgCl2 potentiated the binding by more than 100%. (d) Monoclonal antibodies against TSP and GPIIb-IIIa inhibited the binding by 30-70% as compared with control and polyclonal anti-fibrinogen anti-serum. (e) A plot of GPIIb-IIIa bound versus GPIIb-IIIa added was best described as a rectangular hyperbola by regression analysis with half-saturation at 60 ng/ml GPIIb-IIIa. Similar results were obtained when labeled TSP was added to tubes coated with GPIIb-IIIa. These results show that TSP and GPIIb-IIIa can specifically interact in vitro and suggest that GPIIb-IIIa may function as a platelet TSP receptor during platelet aggregation.
Highlights
From the Departmentof Medicine, Medical College of Pennsylvania, Philadelphia, Pennsylvania 19129and the SLankenau Medical Research Center, Philadelphia, Pennsylvania 19151
After 90 min, the binding cleaved from the intacmt olecule by proteolytic enzymes, still bomo1rwtia1fenvao1dcGi,sp.riatoePymlbSagIoIebsetrbutvhyat-ini1eacpm1drnphoa11eoy,ltri0lontySi% lotdnaiehnecdopeTprefihycsetSotaulanhfaPrbtdoemeeeesvde.wnieixdtAdtao,ebhsesngpoangaeeutclnieacnytelonidsfwudiieiscs3anlil.eno-sdyc1(fitf0catarmra-ho)odfTtoepmdoesShelbtddoPotlhreraumiaexbamndstpeodiimlesroeterrhoadiaamcbeGndtGideiliPibovPnzIiaiaIteIntscbIudyd,b--tio-n-gemamgmhreeoaaeSnallinvoengt(ycuts2luaotb)hlihb,aenaaulAtlvanlhsasemderabirettreeryrlveeitipcneggheaaiaeosnlVnehnbdedosoccn-wlbboodanylin,u,lnaanstedgeoeliedcennitcwgneftodrte(eor4abrpnp)ryar.oocmoTtnpthphiiwcenrmeerrgiotteasihcsetdcarseshout.ttepclropyeTtafu.anhcrrledioeonssnnoegs(fti3cThsto)htSra,sreeftdPsoibeifnmrfwsritnaabeigtvoclhe-t-111, than immobilized bovine serum albumin. ( b ) Ad- Platelet aggregation is an important step in the hemostatic dition of unlabeled excess GPIIb-IIIr,eversed the bind- process
Serum. (e) A plot of GPIIb-111, bound versus GPIIb-111, The role of thrombospondin in the mechanism of platelet added was best described as a rectangular hyperbola aggregation and blood coagulation is poorly understood. It is by regression analysis with half-saturation at 60 ngl ml GPIIb-IIIa.Similar results were obtained when labeled TSP was added to tubescoated with GPIII,III,. These results show that TSP GaPnIdIb-111. can interact in vitro and suggest that GP11b-111, may function as a platelet TSP receptorduringplatelet aggregation
Summary
From the Departmentof Medicine, Medical College of Pennsylvania, Philadelphia, Pennsylvania 19129and the SLankenau Medical Research Center, Philadelphia, Pennsylvania 19151. AzAs is directed against the GPIIb-III, complex (lo), andSSAGis GPIII, specific (11).TSP was purified by fibrinogen-Sepharose chromatography from the released proteins of ionophore-stimulated platelets essentially as described previously (2). Binding Assay-The inside surfaces of 3-ml polystyrene test tubes reversible with excess unlabeled GPIIb-111, added 30 min after (Elkay) were coated with either GPIIb-III., bovine serum albumin initiation of binding (Fig. 1).Theseresults indicate that (BSA), fibrinogen, or TSP.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
